BioStock: PHI aims for US listing

July 11, 2024
Language flag

Swedish Medtech Phase Holographic Imaging is making significant strides in the United States, establishing itself at the forefront of the rapidly growing regenerative medicine field. PHI is now taking an important step by applying for listing its shares in the US OTCQB market to enhance its presence and opportunities in the US. BioStock talked to CEO Patrik Eschricht to learn more about what this means for the company.

Read the full interview with Patrik Eschricht on biostock.se.

We are very happy about the possibility of dual-listing on the OTCQB, which would be another significant step in PHI’s growth journey as a global company. This dual listing would make it more accessible for international investors to invest in PHI, positively increasing liquidity, boosting shareholder value, and supporting our ongoing growth.

Further reading

Businesspeople brainstorming together with sticky notes in an of

BioStock: PHI links up with two regenerative medicine networks

BioStock contacted CEO Patrik Eschricht to learn more about the company’s future strategies in regenerative medicine and the pivot toward the clinical market.
BioStock: PHI charts a bold course to impact regenerative medicine

BioStock: PHI charts a bold course to impact regenerative medicine

BioStock contacted CEO Patrik Eschricht to delve into the year-end report’s highlights and shed light on the company’s vision and initiatives.
righst issue of units 2022 banner

BioStock: The five best life science stocks of the first half-year

PHI is proud to be highlighted as one of the top 5 best-performing Swedish life science stocks in the first half of 2023.
PHI-worldtour-1024x576

BioStock: PHI’s CEO reflects on global roadshow success

BioStock contacted CEO Patrik Eschricht to learn about the team’s achievements on their global roadshow this early summer.
123456…8

Latest News

phi-right-moment-to-capitalize-on-regenerative-medicine-momentum

BioStock: PHI’s new CEO: “I am excited to lead us forward with new energy”

Anders Månsson was recently appointed CEO of Phase Holographic Imaging. With extensive leadership experience in the international life sciences sector, he aims to expand PHI’s global reach and position the company as a leader in non-invasive cell quality control technologies. BioStock spoke with him about his vision for the future.

Bulletin from the annual general meeting of Phase Holographic Imaging PHI AB (publ)

Phase Holographic Imaging PHI AB (publ) held its annual general meeting on 31 October 2024. The following resolutions were made.

PHI secures a loan from Altium SA

Phase Holographic Imaging PHI AB (“PHI”) announces that the Company has been provided a loan of SEK 7 million from the main shareholder Altium SA. PHI and Altium SA are also in dialogues regarding long-term financing of PHI.
See All News